Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Multiple Sclerosis and Related Disorders|August 22, 2020
Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practiceMarcello De Angelis, Maria Petracca, Roberta Lanzillo, et al.
Journal of Clinical Medicine|June 2, 2021
Digital Technology in Clinical Trials for Multiple Sclerosis: Systematic ReviewMarcello De Angelis, Luigi Lavorgna, Antonio Carotenuto, et al.
Frontiers in Neurology|July 7, 2020
Single-Center 8-Years Clinical Follow-Up of Cladribine-Treated Patients From Phase 2 and 3 TrialsMarcello Moccia, Roberta Lanzillo, Martina Petruzzo, et al.
BMC Neurology|April 6, 2021
Possible progressive multifocal leukoencephalopathy and active multiple sclerosis under dimethyl fumarate: the central role of MRI in informing therapeutic decisionsElena Augusta Vola, Maria Petracca, Sirio Cocozza, et al.
Multiple Sclerosis and Related Disorders|November 24, 2019
The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosisMartina Petruzzo, Raffaele Palladino, Antonio Nardone, et al.
Multiple Sclerosis and Related Disorders|February 8, 2021
Ocrelizumab depletes T-lymphocytes more than rituximab in multiple sclerosisNicola Capasso, Agostino Nozzolillo, Giulia Scalia, et al.
Journal of Neurology|March 4, 2020
Predictors of Nabiximols (Sativex<sup>®</sup>) discontinuation over long-term follow-up: a real-life studyAntonio Carotenuto, Teresa Costabile, Mario De Lucia, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 28, 2019
Different cortical excitability profiles in hereditary brain iron and copper accumulationRaffaele Dubbioso, Lucia Ruggiero, Marcello Esposito, et al.
Frontiers in Neurology|July 7, 2020
Peripapillary Vessel Density as Early Biomarker in Multiple SclerosisGilda Cennamo, Antonio Carotenuto, Daniela Montorio, et al.
Journal of Clinical Medicine|April 23, 2022
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter StudyRoberta Lanzillo, Antonio Carotenuto, Elisabetta Signoriello, et al.
Pageof 2